AVTX Key Statistics, Chart & Performance
The current stock price of AVTX is 16.95 USD. In the past month the price decreased by -15.04%. In the past year, price increased by 142.14%.
AVTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About AVTX
Company Profile
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Wayne, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Company Info
AVALO THERAPEUTICS INC
1500 Liberty Ridge Drive, Suite 321
Wayne PENNSYLVANIA US
CEO: Michael Cola
Employees: 23
Phone: 14105228707
AVALO THERAPEUTICS INC / AVTX FAQ
Can you describe the business of AVALO THERAPEUTICS INC?
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Wayne, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
What is the stock price of AVALO THERAPEUTICS INC today?
The current stock price of AVTX is 16.95 USD. The price decreased by -0.94% in the last trading session.
Does AVALO THERAPEUTICS INC pay dividends?
AVTX does not pay a dividend.
What is the ChartMill rating of AVALO THERAPEUTICS INC stock?
AVTX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of AVALO THERAPEUTICS INC (AVTX)?
AVALO THERAPEUTICS INC (AVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.31).
What is the next earnings date for AVTX stock?
AVALO THERAPEUTICS INC (AVTX) will report earnings on 2026-03-18, after the market close.
Who owns AVALO THERAPEUTICS INC?
You can find the ownership structure of AVALO THERAPEUTICS INC (AVTX) on the Ownership tab.
AVTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AVTX. When comparing the yearly performance of all stocks, AVTX is one of the better performing stocks in the market, outperforming 95.96% of all stocks.
AVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AVTX. While AVTX has a great health rating, there are worries on its profitability.
AVTX Financial Highlights
Over the last trailing twelve months AVTX reported a non-GAAP Earnings per Share(EPS) of -13.31. The EPS increased by 95.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.77% | ||
| ROE | -109% | ||
| Debt/Equity | 0 |
AVTX Forecast & Estimates
16 analysts have analysed AVTX and the average price target is 34.39 USD. This implies a price increase of 102.88% is expected in the next year compared to the current price of 16.95.
For the next year, analysts expect an EPS growth of 96.32% and a revenue growth -100% for AVTX